LS
Laura Stoppel
Board of Directors at Indapta Therapeutics
Somerville, Massachusetts
Overview
Laura Stoppel is a Principal at RA Capital Management, L.P. with a background in neuroscience and molecular biology. She has served on the Board of Directors for multiple biotech companies and has made strategic investments in various stages and sectors within the industry.
Laura's career highlights include her role as Principal at RA Capital Management, L.P. and her contributions to the success of companies like Nimbus Therapeutics and Indapta Therapeutics through her investments and board positions.
Work Experience
Principal
2020 - Current
Analyst
2020 - 2020
Senior Associate
2018 - 2020
Associate
2016 - 2018
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Board of Directors
2020
Board of Directors
2020
Nimbus Therapeutics uses computational technology to create selective small molecule therapeutics.
Raised $637,000,000.00 from Biotechnology Value Fund, RA Capital Management, Gates Frontier Fund, SR One, Pfizer Venture Investments, Bain Capital Life Sciences, Atlas Venture, Google Ventures, SV Health Investors and Lightstone Ventures.
Board of Directors
2020
Acumen is developing targeted therapies for the safe and effective treatment of Alzheimer’s Disease and related neurodegenerative diseases.
Raised $295,100,000.00 from K2 HealthVentures.
Board of Directors
2022
Board Observer
2019 - 2021
Education
Doctor of Philosophy (PhD)
2011 - 2016
BA
2004 - 2008